Oxidative mechanisms and tardive dyskinesia

James B. Lohr, Ronald Kuczenski, Alexander Niculescu

Research output: Contribution to journalArticle

175 Citations (Scopus)

Abstract

Tardive dyskinesia has been and continues to be a significant problem associated with long-term antipsychotic use, but its pathophysiology remains unclear. In the last 10 years, preclinical studies of the administration of antipsychotics to animals, as well as clinical studies of oxidative processes in patients given antipsychotic medications, with and without tardive dyskinesia, have continued to support the possibility that neurotoxic free radical production may be an important consequence of antipsychotic treatment, and that such production may relate to the development of dyskinetic phenomena. In line with this hypothesis, evidence has accumulated for the efficacy of antioxidants, primarily vitamin E (α-tocopherol), in the treatment and prevention of tardive dyskinesia. Early studies suggested a modest effect of vitamin E treatment on existing tardive dyskinesia, but later studies did not demonstrate a significant effect. Because evidence has continued to accumulate for increased oxidative damage from antipsychotic medications, but less so for the effectiveness of vitamin E, especially in cases of long-standing tardive dyskinesia, alternative antioxidant approaches to the condition may be warranted. These approaches may include the use of antioxidants as a preventive measure for tardive dyskinesia or the use of other antioxidants or neuroprotective drugs, such as melatonin, for established tardive dyskinesia.

Original languageEnglish (US)
Pages (from-to)47-62
Number of pages16
JournalCNS Drugs
Volume17
Issue number1
DOIs
StatePublished - 2003
Externally publishedYes

Fingerprint

Antipsychotic Agents
Antioxidants
Vitamin E
Tocopherols
Neuroprotective Agents
Melatonin
Tardive Dyskinesia
Free Radicals
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Neuropsychology and Physiological Psychology
  • Pharmacology

Cite this

Oxidative mechanisms and tardive dyskinesia. / Lohr, James B.; Kuczenski, Ronald; Niculescu, Alexander.

In: CNS Drugs, Vol. 17, No. 1, 2003, p. 47-62.

Research output: Contribution to journalArticle

Lohr, James B. ; Kuczenski, Ronald ; Niculescu, Alexander. / Oxidative mechanisms and tardive dyskinesia. In: CNS Drugs. 2003 ; Vol. 17, No. 1. pp. 47-62.
@article{30e8a905784d4db6bb05bef9b22ffaf1,
title = "Oxidative mechanisms and tardive dyskinesia",
abstract = "Tardive dyskinesia has been and continues to be a significant problem associated with long-term antipsychotic use, but its pathophysiology remains unclear. In the last 10 years, preclinical studies of the administration of antipsychotics to animals, as well as clinical studies of oxidative processes in patients given antipsychotic medications, with and without tardive dyskinesia, have continued to support the possibility that neurotoxic free radical production may be an important consequence of antipsychotic treatment, and that such production may relate to the development of dyskinetic phenomena. In line with this hypothesis, evidence has accumulated for the efficacy of antioxidants, primarily vitamin E (α-tocopherol), in the treatment and prevention of tardive dyskinesia. Early studies suggested a modest effect of vitamin E treatment on existing tardive dyskinesia, but later studies did not demonstrate a significant effect. Because evidence has continued to accumulate for increased oxidative damage from antipsychotic medications, but less so for the effectiveness of vitamin E, especially in cases of long-standing tardive dyskinesia, alternative antioxidant approaches to the condition may be warranted. These approaches may include the use of antioxidants as a preventive measure for tardive dyskinesia or the use of other antioxidants or neuroprotective drugs, such as melatonin, for established tardive dyskinesia.",
author = "Lohr, {James B.} and Ronald Kuczenski and Alexander Niculescu",
year = "2003",
doi = "10.2165/00023210-200317010-00004",
language = "English (US)",
volume = "17",
pages = "47--62",
journal = "CNS Drugs",
issn = "1172-7047",
publisher = "Adis International Ltd",
number = "1",

}

TY - JOUR

T1 - Oxidative mechanisms and tardive dyskinesia

AU - Lohr, James B.

AU - Kuczenski, Ronald

AU - Niculescu, Alexander

PY - 2003

Y1 - 2003

N2 - Tardive dyskinesia has been and continues to be a significant problem associated with long-term antipsychotic use, but its pathophysiology remains unclear. In the last 10 years, preclinical studies of the administration of antipsychotics to animals, as well as clinical studies of oxidative processes in patients given antipsychotic medications, with and without tardive dyskinesia, have continued to support the possibility that neurotoxic free radical production may be an important consequence of antipsychotic treatment, and that such production may relate to the development of dyskinetic phenomena. In line with this hypothesis, evidence has accumulated for the efficacy of antioxidants, primarily vitamin E (α-tocopherol), in the treatment and prevention of tardive dyskinesia. Early studies suggested a modest effect of vitamin E treatment on existing tardive dyskinesia, but later studies did not demonstrate a significant effect. Because evidence has continued to accumulate for increased oxidative damage from antipsychotic medications, but less so for the effectiveness of vitamin E, especially in cases of long-standing tardive dyskinesia, alternative antioxidant approaches to the condition may be warranted. These approaches may include the use of antioxidants as a preventive measure for tardive dyskinesia or the use of other antioxidants or neuroprotective drugs, such as melatonin, for established tardive dyskinesia.

AB - Tardive dyskinesia has been and continues to be a significant problem associated with long-term antipsychotic use, but its pathophysiology remains unclear. In the last 10 years, preclinical studies of the administration of antipsychotics to animals, as well as clinical studies of oxidative processes in patients given antipsychotic medications, with and without tardive dyskinesia, have continued to support the possibility that neurotoxic free radical production may be an important consequence of antipsychotic treatment, and that such production may relate to the development of dyskinetic phenomena. In line with this hypothesis, evidence has accumulated for the efficacy of antioxidants, primarily vitamin E (α-tocopherol), in the treatment and prevention of tardive dyskinesia. Early studies suggested a modest effect of vitamin E treatment on existing tardive dyskinesia, but later studies did not demonstrate a significant effect. Because evidence has continued to accumulate for increased oxidative damage from antipsychotic medications, but less so for the effectiveness of vitamin E, especially in cases of long-standing tardive dyskinesia, alternative antioxidant approaches to the condition may be warranted. These approaches may include the use of antioxidants as a preventive measure for tardive dyskinesia or the use of other antioxidants or neuroprotective drugs, such as melatonin, for established tardive dyskinesia.

UR - http://www.scopus.com/inward/record.url?scp=0037223482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037223482&partnerID=8YFLogxK

U2 - 10.2165/00023210-200317010-00004

DO - 10.2165/00023210-200317010-00004

M3 - Article

C2 - 12467492

AN - SCOPUS:0037223482

VL - 17

SP - 47

EP - 62

JO - CNS Drugs

JF - CNS Drugs

SN - 1172-7047

IS - 1

ER -